V. Duric

909 total citations
17 papers, 716 citations indexed

About

V. Duric is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, V. Duric has authored 17 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in V. Duric's work include Breast Cancer Treatment Studies (7 papers), BRCA gene mutations in cancer (4 papers) and Global Cancer Incidence and Screening (4 papers). V. Duric is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), BRCA gene mutations in cancer (4 papers) and Global Cancer Incidence and Screening (4 papers). V. Duric collaborates with scholars based in Australia, United Kingdom and Austria. V. Duric's co-authors include Martin R. Stockler, Alan S. Coates, Pernille Tine Jensen, Ann‐Charlotte Waldenström, Dariusz Wydra, Vesna Bjelic Radisic, Elfriede Greimel, Susanne Singer, Wei‐Chu Chie and Andy Nordin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

V. Duric

14 papers receiving 706 citations

Peers

Countries citing papers authored by V. Duric

Since Specialization

Citations

This map shows the geographic impact of V. Duric's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Duric with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Duric more than expected).

Fields of papers citing papers by V. Duric

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Duric. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Duric. The network helps show where V. Duric may publish in the future.

Co-authorship network of co-authors of V. Duric

This figure shows the co-authorship network connecting the top 25 collaborators of V. Duric. A scholar is included among the top collaborators of V. Duric based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Duric. V. Duric is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Lung cancer clinicians’ preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile? 2010 ·Lung Cancer ·Prunella Blinman, Sue‐Anne McLachlan, Anna K. Nowak, V. Duric, Chris Brown, Gavin Wright, Michael Millward, Kwun M. Fong, Martin R. Stockler	16
2	Patients’ preferences for chemotherapy in non-small-cell lung cancer: A systematic review 2010 ·Lung Cancer ·Prunella Blinman, Mahmood Alam, V. Duric, Sue‐Anne McLachlan, Martin R. Stockler	52
3	Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? 2010 ·European Journal of Cancer ·Prunella Blinman, V. Duric, Anna K. Nowak, Philip Beale, Stephen Clarke, Karen Briscoe, Adam Boyce, David Goldstein, Harold Hudson, Martin R. Stockler	33
4	Comparing patients’ and their partners’ preferences for adjuvant chemotherapy in early breast cancer 2008 ·Patient Education and Counseling ·V. Duric, Phyllis Butow, Louise Sharpe, Stéphane Héritier, Frances Boyle, Jane Beith, Nicholas Wilcken, Alan S. Coates, R. J. Simes, Martin R. Stockler	19
5	Preferences for adjuvant chemotherapy (ACT) in early breast cancer: The benefits needed to make extended treatment with docetaxel, doxorubicin, and CMF worthwhile 2007 ·Journal of Clinical Oncology ·V. Duric, Prudence A. Francis, (unknown), Arlene Chan, Jacquie Chirgwin, V. Harvey, (unknown), R. J. Simes, Alan S. Coates, Martin R. Stockler	2
6	Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer 2006 ·Psycho-Oncology ·V. Duric, Phyllis Butow, Louise Sharpe, Frances Boyle, Jane Beith, Nicholas Wilcken, Stéphane Héritier, Alan S. Coates, R. John Simes, Martin R. Stockler	41
7	The European Organization for Research and Treatment of Cancer (EORTC) Quality‐of‐Life questionnaire cervical cancer module 2006 ·Cancer ·Elfriede Greimel, (unknown), Ann‐Charlotte Waldenström, V. Duric, Pernille Tine Jensen, Susanne Singer, Wei‐Chu Chie, Andy Nordin, Vesna Bjelic Radisic, Dariusz Wydra	228
8	264 POSTER Patient preferences for adjuvant radiotherapy in early breast cancer - an Australian sub-study of the pilot TARGIT study 2006 ·European Journal of Surgical Oncology ·Deepa Joseph, Anna K. Nowak, Tammy Corica, Christobel Saunders, Catherine A. Herbert, Mahesh Bulsara, V. Duric	4
9	Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? 2005 ·Annals of Oncology ·V. Duric, Martin R. Stockler, Stéphane Héritier, F. Boyle, Jane Beith, A. Sullivan, Nicholas Wilcken, Alan S. Coates, R. J. Simes	100
10	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? 2005 ·The Lancet Oncology ·Belinda Thewes, Bettina Meiser, V. Duric, Martin R. Stockler, Alan Taylor, Robin Stuart‐Harris, Matthew Links, Nicholas Wilcken, Sue Anne McLachlan, Kelly‐Anne Phillips, Jane Beith, Frances Boyle, Michael Friedländer	51
11	Patients’ preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? 2005 ·British Journal of Cancer ·V. Duric, Lesley Fallowfield, Christobel Saunders, J. Houghton, Alan S. Coates, Martin R. Stockler	40
12	Comparing patients’ and their partners’ preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC) 2005 ·Journal of Clinical Oncology ·V. Duric, Martin R. Stockler, PN Butow, Louise Sharpe, Stéphane Héritier, Jane Beith, F. Boyle, Nicholas Wilcken, Alan S. Coates, R. J. Simes	2
13	Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC) 2004 ·Journal of Clinical Oncology ·V. Duric, Martin R. Stockler, PN Butow, Louise Sharpe, Jane Beith, (unknown), F. Boyle, Haryana M. Dhillon, Alan S. Coates, R. J. Simes	0
14	Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC) 2004 ·Journal of Clinical Oncology ·V. Duric, Martin R. Stockler, Phyllis Butow, Louise Sharpe, Jane Beith, (unknown), F. Boyle, Haryana M. Dhillon, Alan S. Coates, R. J. Simes	0
15	Reducing Psychological Distress in a Genetic Counseling Consultation for Breast Cancer 2003 ·Journal of Genetic Counseling ·V. Duric, Phyllis Butow, Louise Sharpe, Elizabeth Lobb, Bettina Meiser, Alexandra Barratt, Katherine Tucker	43
16	Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile? 2001 ·The Lancet Oncology ·V. Duric, Martin R. Stockler	84
17	Performance realism in test-anxious students 1996 ·Anxiety Stress & Coping ·Susan H. Spence, V. Duric, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact